Artivion, Inc.

Artivion Reports Second Quarter 2026 Financial Results

Artivion reported second quarter revenue of $125.8 million, up 11% year-over-year, driven by 18% growth in On-X mechanical heart valves and 12% growth in stent grafts. During the quarter, the company achieved two major strategic milestones: the completion of the Endospan acquisition and the U.S. FDA PMA approval of the AMDS Hybrid Prosthesis. Management reaffirmed full-year 2026 guidance for revenue of $480-$496 million and adjusted EBITDA of $92-$99 million, citing confidence in the expanded aortic arch portfolio.

•2mo ago

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

Artivion received FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute Debakey Type I aortic dissections, eliminating the need for institutional review board approval. The approval is supported by data from the PERSEVERE trial, which demonstrated a 72% reduction in all-cause mortality and zero occurrence of DANE tears at 30 days compared to standard care. This regulatory milestone allows Artivion to fully penetrate an estimated $150 million annual U.S. market and accelerates adoption of the technology.

•3mo ago

AORT: 8-K · acquisition merger

Artivion, Inc. (AORT) announced the completion of its acquisition of Endospan Ltd., an Israeli developer of aortic instability treatments. The deal was consummated pursuant to a previously announced option agreement, with Artivion paying a net purchase price of approximately $131.3 million in cash after offsetting existing loans. The base purchase price was $175.0 million, subject to adjustments for working capital, debt, and transaction expenses. A portion of the consideration was held in escrow, including $16.5 million for indemnification and $1.0 million for purchase price adjustments. Securityholders of Endospan are entitled to receive up to $200.0 million in contingent consideration based on the future performance of the Nexus™ product. This payment will be determined and payable approximately two years following the closing, adding significant variable cost to the acquisition.

SEC 8-K•5mo ago

Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System

Artivion (NYSE: AORT) has closed its acquisition of Endospan, a pioneer in endovascular solutions for complex aortic pathologies. The deal follows the April 2026 FDA PMA approval of Endospan’s NEXUS Aortic Arch System, the first off-the-shelf endovascular solution for aortic arch disease. The base purchase price is $175 million (less loan offsets), with up to $200 million in additional earn-out consideration tied to U.S. commercial performance over two years. Artivion stated the acquisition completes its market-leading, three-pronged aortic arch portfolio, combining NEXUS with its existing AMDS and ARCEVO LSA products.

•5mo ago

Artivion Completes Acquisition of Endospan Ltd.

Artivion has completed its acquisition of Endospan Ltd., a pioneer in endovascular repair of aortic arch disease, for an upfront net purchase price of $135 million. The transaction was funded using a previously drawn $150 million delayed draw term loan, avoiding the need for new dilutive equity financing or additional debt issuance at closing. This acquisition completes Artivion’s three-pronged aortic arch portfolio, combining the NEXUS system with its existing AMDS and ARCEVO LSA products to create a unique global position as the only company with a complete suite of aortic arch solutions.

•5mo ago